Caris Life Sciences (Caris), a frontrunner in AI-driven precision medicine, and COTA, Inc., a specialist in real-world data (RWD) and analytics, have unveiled a strategic partnership. The collaboration seeks to revolutionise cancer treatment advancement and patient well-being by harnessing a potent blend of data: Caris’ expansive molecular data and COTA’s real-world patient insights.
This joint effort harnesses remarkable resources:
- Caris’ Molecular Proficiency: Caris possesses an extensive molecular repository, comprising nearly 10 million tests and housing over 60 petabytes of data. This encompasses genomic, transcriptomic, proteomic, and imaging data, furnishing a holistic view of each patient’s cancer.
- COTA’s Real-World Intelligence: COTA furnishes real-world data from a pool of over 2 million cancer patients treated across varied healthcare environments. This data encapsulates patients’ actual treatment paths and outcomes, offering invaluable insights into real-world efficacy.
By amalgamating these datasets, the collaboration aims to forge a distinctive, large-scale, multi-faceted data solution. This will empower researchers and pharmaceutical entities to:
- Pioneer More Efficient Cancer Therapeutics: The comprehensive view of patients’ molecular profiles and real-world treatment responses will steer the development of targeted and personalised cancer remedies.
- Facilitate Drug Discovery Expediency: The wealth of data will expedite the identification of promising drug candidates and the streamlining of clinical trials.
- Enhance Patient Well-being: Ultimately, the collaboration endeavours to translate data-driven insights into enhanced patient well-being by facilitating the creation of more effective and personalised cancer interventions.
Brian Lamon, PhD, Chief Business Officer at Caris commented “Caris’ partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development. This breadth of data allows the flexibility to build specific cohorts for understanding mechanisms of resistance, determinants of response and relevant biomarkers to improve success of their clinical trials.”
Click here to read the original news story.